Where Wealthy Investors Are Quietly Moving Their Money

Jan de Vries · 2026-10-12

There's a shift happening in private capital right now, and it's hard to miss once you see the numbers. Wealthy investors, family offices, high-net-worth individuals — they're all steering serious money toward two sectors: artificial intelligence and health technology. The question isn't whether this is happening. It's why. Let's dig into what's driving it. ### The EU Is Betting Big — and Investors Are Watching The European Union isn't shy about its ambitions. Its InvestAI initiative aims to mobilize roughly €200 billion (about $216 billion) for artificial intelligence, including funding for major AI infrastructure. That's not pocket change. It's a signal. On the healthcare side, the European Commission and the European Investment Bank Group launched BioTechEU, designed to mobilize €10 billion (around $10.8 billion) for biotech and life sciences across 2026 and 2027. That public push is happening alongside a private one. The UBS Global Family Office Report 2026 found that 65% of family offices were already invested in AI, and 33% had allocations to AI-enabled healthcare. When public money and private money move in the same direction, people notice. ### Why the Infrastructure Matters Infrastructure is often the clearest tell. In July 2026, the EU requested up to seven AI Gigafactories, backed by up to €10 billion (about $10.8 billion) in EU and national funding. The expectation? At least €20 billion (roughly $21.6 billion) in additional private investment flowing in behind it. Life sciences already contribute nearly €1.5 trillion (around $1.62 trillion) in value to the EU economy and support 29 million jobs. The EU's broader strategy also includes making multi-country clinical trials easier to fund and €300 million (about $324 million) to stimulate procurement of innovations like next-generation vaccines and affordable cancer solutions. ### AI and HealthTech: Where the Growth Actually Shows Up By April 2026, 19 AI Factories had been deployed across European supercomputers, supported by 13 regional antennas. EU and participating EuroHPC countries committed more than €2.6 billion (about $2.8 billion) to that initiative alone. Then there's the healthcare data layer. The European Health Data Space is built to make health data easier to access and reuse securely for research and innovation. Cancer Image Europe is expected to provide access to 60 million cancer images by the end of 2026. The 1+ Million Genomes initiative aims to open secure access to genomic and clinical data. And AI is moving from the lab into real clinical settings. In 2026, the European Commission made €9 million (roughly $9.7 million) available for two large-scale pilots of AI-powered medical imaging — covering X-rays, CT scans, MRI, PET and ultrasound. That last point matters for investors. HealthTech is no longer just laboratory research. It's real-world clinical testing backed by EU deployment programs. ### The Capital Rotation Nobody Can Fully Track Here's the honest part: it's difficult to track exactly what every high-net-worth individual is investing in. Much private investment isn't publicly disclosed. > "Family offices don't publish their allocation sheets. But when you talk to them, the conversation keeps landing on the same two themes: AI infrastructure and clinical-stage health technology." What we can see is the direction of travel. Public funding is de-risking early infrastructure. Data platforms are maturing. Clinical pilots are moving forward. And private capital tends to follow where the risk curve flattens. For investors watching Europe, the story isn't just about hype. It's about a continent building the rails — compute, data, and clinical pathways — that the next wave of AI and HealthTech companies will run on. That's a different kind of opportunity. And it's one worth paying attention to.